Download PDF
Horm Metab Res 2023; 55(01): 65-74
DOI: 10.1055/a-1984-0255
Original Article: Endocrine Research

Aprotinin does not Impair Vascular Function in Patients Undergoing Coronary Artery Bypass Graft Surgery

Josephine Tolkmitt
1   Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
,
Heike Brendel
1   Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
,
Birgit Zatschler
2   Institute of Physiology, Technische Universität Dresden, Dresden, Germany
,
Stefan Brose
3   Department of Cardiac Surgery, University Heart Center Dresden, Technische Universität Dresden, Dresden, Germany
,
Coy Brunssen
4   Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
,
Irakli Kopaliani
2   Institute of Physiology, Technische Universität Dresden, Dresden, Germany
,
Andreas Deussen
2   Institute of Physiology, Technische Universität Dresden, Dresden, Germany
,
Klaus Matschke
3   Department of Cardiac Surgery, University Heart Center Dresden, Technische Universität Dresden, Dresden, Germany
,
Henning Morawietz
1   Department of Medicine III, Division of Vascular Endothelium and Microcirculation, Technische Universität Dresden, Dresden, Germany
› Author Affiliations Funding Information Else Kröner-Fresenius-Stiftung — http://dx.doi.org/10.13039/ 501100003042; 2010_A105; Deutsches Zentrum für Herz-Kreislaufforschung — http://dx.doi.org/10.13039/100010447; 81 × 2800207; Excellence Initiative by the German Federal and State Governments (Institutional Strategy, measure ‘support the best’) — 3–25 2, Grant F-03661–553–41B-1250000; Deutsche Forschungsgemeinschaft — http://dx.doi.org/10.13039/501100001659; 47081312
› Further Information
Also available at
    Permissions and Reprints

Abstract

Bleeding is a major complication in coronary artery bypass graft surgery. Antifibrinolytic agents like serine protease inhibitor aprotinin can decrease postoperative bleeding and complications of cardiac surgery. However, the effects of aprotinin on vascular function are not completely elucidated. We compared the ex vivo vascular function of left internal mammary arteries from patients undergoing coronary artery bypass graft surgery with and without intraoperative application of aprotinin using a Mulvany Myograph. Human internal mammary arteries were treated with aprotinin ex vivo and tested for changes in vascular function. We analyzed the impact of aprotinin on vascular function in rat aortic rings. Finally, impact of aprotinin on expression and activity of endothelial nitric oxide synthase was tested in human endothelial cells. Intraoperative application of aprotinin did not impair ex vivo vascular function of internal mammary arteries of patients undergoing coronary artery bypass graft surgery. Endothelium-dependent and -independent relaxations were not different in patients with or without aprotinin after nitric oxide synthase blockade. A maximum vasorelaxation of 94.5%±11.4vs. 96.1%±5.5% indicated a similar vascular smooth muscle function in both patient groups (n=13 each). Long-term application of aprotinin under physiological condition preserved vascular function of the rat aorta. In vitro application of increasing concentrations of aprotinin on human endothelial cells resulted in a similar expression and activity of endothelial nitric oxide synthase. In conclusion, intraoperative and ex vivo application of aprotinin does not impair the endothelial function in human internal mammary arteries and experimental models.

Key words

aprotinin - coronary artery bypass graft surgery - endothelial cells - nitric oxide - vascular function


Publication History

Received: 15 August 2022

Accepted after revision: 14 November 2022

Article published online:
04 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Jimenez Rivera JJ, Iribarren JL, Raya JM. et al. Factors associated with excessive bleeding in cardiopulmonary bypass patients: a nested case-control study. J Cardiothorac Surg 2007; 2: 17
    CrossrefPubMedGoogle Scholar
  • 2 Howell N, Senanayake E, Freemantle N. et al. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2013; 145: 234-240
    CrossrefPubMedGoogle Scholar
  • 3 Waldow T, Krutzsch D, Wils M. et al. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass. Clin Hemorheol Microcirc 2009; 42: 269-277
    CrossrefPubMedGoogle Scholar
  • 4 Sodha NR, Boodhwani M, Bianchi C. et al. Aprotinin in cardiac surgery. Expert Rev Cardiovasc Ther 2006; 4: 151-160
    CrossrefPubMedGoogle Scholar
  • 5 Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-983
    PubMedGoogle Scholar
  • 6 Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80: 1013-1018
    CrossrefPubMedGoogle Scholar
  • 7 Royston D, Bidstrup BP, Taylor KM. et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-1291
    CrossrefPubMedGoogle Scholar
  • 8 Smith CR. Management of bleeding complications in redo cardiac operations. Ann Thorac Surg 1998; 65: S2-S8
    CrossrefPubMedGoogle Scholar
  • 9 Mangano DT, Tudor IC, Dietzel C. et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365
    CrossrefPubMedGoogle Scholar
  • 10 Schneeweiss S, Seeger JD, Landon J. et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771-783
    CrossrefPubMedGoogle Scholar
  • 11 Shaw AD, Stafford-Smith M, White WD. et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784-793
    CrossrefPubMedGoogle Scholar
  • 12 Fergusson DA, Hebert PC, Mazer CD. et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331
    CrossrefPubMedGoogle Scholar
  • 13 Kristeller JL, Roslund BP, Stahl RF. Benefits and risks of aprotinin use during cardiac surgery. Pharmacotherapy 2008; 28: 112-124
    CrossrefPubMedGoogle Scholar
  • 14 European Medicines Agency 2013. https://www.ema.europa.eu/en/documents/referral/questions-answers-review-antifibrinolytic-medicines-aprotinin-aminocaproic-acid-tranexamic-acid_en.pdf; Accessed September 18, 2013
    PubMed
  • 15 Hebert PC, Fergusson DA, Hutton B. et al. Regulatory decisions pertaining to aprotinin may be putting patients at risk. CMAJ 2014; 186: 1379-1386
    CrossrefPubMedGoogle Scholar
  • 16 Walkden GJ, Verheyden V, Goudie R. et al. Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Med 2013; 39: 1808-1817
    CrossrefPubMedGoogle Scholar
  • 17 Royston D, De Hert S, van der Linden J. et al. A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med 2017; 36: 97-102
    CrossrefPubMedGoogle Scholar
  • 18 Benedetto U, Altman DG, Gerry S. et al. Safety of perioperative aprotinin administration during isolated coronary artery bypass graft surgery: insights from the ART (Arterial Revascularization Trial). J Am Heart Assoc 2018; 7: e007570
    CrossrefPubMedGoogle Scholar
  • 19 Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109: 1007-1009
    CrossrefPubMedGoogle Scholar
  • 20 Ishizawa K, Izawa Y, Ito H. et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005; 46: 1046-1052
    CrossrefPubMedGoogle Scholar
  • 21 Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009; 5: 89-100
    CrossrefPubMedGoogle Scholar
  • 22 Hofmann A, Brunssen C, Wolk S. et al. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection?. J Am Heart Assoc 2020; 9: e013803
    CrossrefPubMedGoogle Scholar
  • 23 Morawietz H, Rueckschloss U, Niemann B. et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899-902
    CrossrefPubMedGoogle Scholar
  • 24 Niemann B, Rohrbach S, Miller MR. et al. Oxidative stress and cardiovascular risk: obesity, diabetes, smoking, and pollution: Part 3 of a 3-Part series. J Am Coll Cardiol 2017; 70: 230-251
    CrossrefPubMedGoogle Scholar
  • 25 Punch E, Klein J, Diaba-Nuhoho P. et al. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 2022; 11: e023328
    CrossrefPubMedGoogle Scholar
  • 26 Siow RC, Li FY, Rowlands DJ. et al. Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 2007; 42: 909-925
    CrossrefPubMedGoogle Scholar
  • 27 Sealey JE, Atlas SA, Laragh JH. et al. Activation of a prorenin-like substance in human plasma by trypsin and by urinary kallikrein. Hypertension 1979; 1: 179-189
    CrossrefPubMedGoogle Scholar
  • 28 Derkx FH, Bouma BN, Schalekamp MP. et al. An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 1979; 280: 315-316
    CrossrefPubMedGoogle Scholar
  • 29 Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Lond) 1998; 94: 505-509
    CrossrefPubMedGoogle Scholar
  • 30 Hill GE, Springall DR, Robbins RA. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 1997; 121: 449-455
    CrossrefPubMedGoogle Scholar
  • 31 Cybularz M, Langbein H, Zatschler B. et al. Endothelial function and gene expression in perivascular adipose tissue from internal mammary arteries of obese patients with coronary artery disease. Atheroscler Suppl 2017; 30: 149-158
    CrossrefPubMedGoogle Scholar
  • 32 Morawietz H, Erbs S, Holtz J. et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006; 114: I296-I301
    CrossrefPubMedGoogle Scholar
  • 33 Zatschler B, Dieterich P, Muller B. et al. Improved vessel preservation after 4 days of cold storage: experimental study in rat arteries. J Vasc Surg 2009; 50: 397-406
    CrossrefPubMedGoogle Scholar
  • 34 Riedel K, Deussen AJ, Tolkmitt J. et al. Estrogen determines sex differences in adrenergic vessel tone by regulation of endothelial beta-adrenoceptor expression. Am J Physiol Heart Circ Physiol 2019; 317: H243-H254
    CrossrefPubMedGoogle Scholar
  • 35 Goettsch C, Goettsch W, Brux M. et al. Arterial flow reduces oxidative stress via an antioxidant response element and Oct-1 binding site within the NADPH oxidase 4 promoter in endothelial cells. Basic Res Cardiol 2011; 106: 551-561
    CrossrefPubMedGoogle Scholar
  • 36 Schubert A, Cattaruzza M, Hecker M. et al. Shear stress-dependent regulation of the human beta-tubulin folding cofactor D gene. Circ Res 2000; 87: 1188-1194
    CrossrefPubMedGoogle Scholar
  • 37 Giebe S, Hofmann A, Brux M. et al. Comparative study of the effects of cigarette smoke versus next generation tobacco and nicotine product extracts on endothelial function. Redox Biol 2021; 47: 102150
    CrossrefPubMedGoogle Scholar
  • 38 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45
    CrossrefPubMedGoogle Scholar
  • 39 Allen S, Anastasiou N, Royston D. et al. Effect of aprotinin on vascular reactivity of coronary bypass grafts. J Thorac Cardiovasc Surg 1997; 113: 319-326
    CrossrefPubMedGoogle Scholar
  • 40 Veres G, Radovits T, Schultz H. et al. Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg 2007; 32: 340-345
    CrossrefPubMedGoogle Scholar
  • 41 Ulker S, Cinar MG, Bayraktutan U. et al. Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. Cardiovasc Res 2001; 50: 589-596
    CrossrefPubMedGoogle Scholar
  • 42 Ulker S, McKeown PP, Bayraktutan U. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res 2002; 55: 830-837
    CrossrefPubMedGoogle Scholar
  • 43 Pruefer D, Makowski J, Dahm M. et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg 2003; 75: 210-215
    CrossrefPubMedGoogle Scholar
  • 44 Asimakopoulos G, Lidington EA, Mason J. et al. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 2001; 122: 123-128
    CrossrefPubMedGoogle Scholar
  • 45 Day JR, Taylor KM, Lidington EA. et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2006; 131: 21-27
    CrossrefPubMedGoogle Scholar
  • 46 Day JR, Punjabi PP, Randi AM. et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110: 2597-2600
    CrossrefPubMedGoogle Scholar
  • 47 Julius U, Schatz U, Tselmin S. et al. COVID-19 and lipid disorders. Horm Metab Res 2022; 54: 514-521
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Redondo-Calvo FJ, Padin JF, Munoz-Rodriguez JR. et al. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. Eur J Clin Invest 2022; 52: e13776
    CrossrefPubMedGoogle Scholar